[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Archer-Daniels-Midland Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":160},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,83,105,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100639426","effect-of-a-probiotic-or-postbiotic-on-gut-microbiome-during-antibiotic-treatment-100639426",false,"NCT07594860","Effect of a Probiotic or Postbiotic on Gut Microbiome During Antibiotic Treatment","Assessment Of Gut Microbiome Changes During Antibiotic Treatment With Probiotic, Postbiotic Or Placebo: A Randomized, Triple-blind, Placebo-controlled Pilot Study.","POTATO-2","Inclusion Criteria:\n\nParticipants meeting ALL of the following criteria will be recruited for the study:\n\n* Males and females aged ≥18 to ≤ 65 years; if female, either not of childbearing potential or using a medically approved method of birth control and willing to take a pregnancy test at screening.\n* Body mass index (BMI) 18.5-29.9 kg\u002Fm².\n* Healthy as determined by medical history and physical examination.\n* Agreed not to change current dietary habits during the course of the study.\n* Able to attend study visits, comply with study requirements (consumption of study medications, especially biological sample collection procedures, and study visit schedule) and provide reliable and complete data regarding AEs\u002FSAEs and PROs.\n* Have been informed and have given written consent for the use of their data in accordance with local regulations before study inclusion.\n\nExclusion Criteria:\n\nParticipants meeting ANY of the following criteria will be excluded from the study:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the study.\n* People on vegetarian or vegan diet; People on special diet (e.g. Ducan, Keto, etc.)\n* BMI ≥ 30 kg\u002Fm² or \\\u003C18.5 kg\u002Fm².\n* History of intake of antibiotics, other probiotics, postbiotics, prebiotics, synbiotics, proton pump inhibitors, acid sequestrants (cholestyramine, Bile colestipol), within six months prior to the screening day.\n* Participation in other clinical trials in the last 90 days prior to screening.\n* Allergy to any penicillin antibiotic or any other beta-lactam agent (e.g. cephalosporin, carbapenem or monobactam).\n* History of jaundice\u002Fhepatic impairment due to amoxicillin\u002Fclavulanic acid.\n* Active smokers or using any form of smokeless tobacco.\n* Participants with substance abuse problems (within two years) defined as:\n\n  * Use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.)\u002F Nicotine dependence.\n  * High-risk drinking as defined by the consumption of four or more alcohol-containing beverages on any day or eight or more alcohol-containing beverages per week for women and five or more alcohol-containing beverages on any day or 15 or more alcohol-containing beverages per week for men.\n* Participants having clinically significant illnesses of cardiovascular, endocrine, immune, respiratory, hepato-biliary, kidney and urinary, haematological, musculoskeletal system and\u002For any inflammatory disorder, tumour, and other gastrointestinal diseases.\n* Participants with a history of bariatric surgery or surgical resection of the stomach, small intestine, or large intestine.\n* Participants actively using GLP1 agonist drugs (Wegovy, Semiglutide etc.) or completed treatment with said medication less than 12 weeks before screening.\n* Any condition that could, in the opinion of the Investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},126,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study assesses the effects of a probiotic or postbiotic on gut microbiome during antibiotic treatment.",[29],"Microbiome",[31,32,33,34,35,36,37,38],"Antibiotic","Dysbiosis","Microbiome composition","Antibiotic Resistance Genes","Microbiome Recovery","Antibiotic Scarring","Probiotic","Postbiotic","NOT_YET_RECRUITING","2026-05-12",{"date":42,"type":43},"2026-05-19","ACTUAL",{"date":45,"type":23},"2026-06-01",{"date":47,"type":23},"2027-05-31",{"name":49,"class":50},"The Archer-Daniels-Midland Company","INDUSTRY",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100472484","study-to-evaluate-the-efficacy-of-a-probiotic-in-infantile-colic-symptoms-relief-100472484","NCT05432479","Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief","A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief","PIXAR","Inclusion Criteria:\n\n* Gestational age of minimum 37 weeks.\n* Birthweight of minimum 2500 g (5.5 lb.).\n* Age of greater than 3 weeks and less than 12 weeks at enrolment.\n* Confirmed Infantile colic defined as: parental report of crying and\u002For fussing ≥3 hours\u002Fday for ≥3 days\u002Fweek, confirmed prior to enrolment with an infant behaviour diary recording \\>3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period \\& for duration of study).\n* Participant Informed Consent form signed by parent or legal guardian.\n* Infant is considered healthy following physical exam.\n* Parents\u002FCaregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits\n\nExclusion Criteria:\n\n* Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.\n* Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).\n* Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).\n* Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.\n* Failure to thrive.\n* Known lactose or gluten intolerance.\n* Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.\n* Known other causes for abdominal pain (e.g., pyloric stenosis).\n* Participation in any other interventional clinical study.\n* Immuno-compromised participant or participant with other severe chronic disorder.\n* Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.\n* Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.\n* Any Participant\u002FParent\u002FCaregiver who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.","3 Weeks","12 Weeks",{"count":63,"type":23},80,[26],"This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.",[67],"Infantile Colic",[69,70,71,72],"probiotic","Bifidobacterium","colic","cry","RECRUITING","2025-04-08",{"date":76,"type":43},"2025-04-09",{"date":78,"type":43},"2022-09-30",{"date":80,"type":23},"2026-05",{"name":49,"class":50},2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":24,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100570004","changes-in-amino-acid-absorption-after-adding-a-probiotic-to-an-acute-protein-feeding-100570004","NCT06701604","Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding","Comparative Differences of Amino Acid Appearance with Milk Protein Ingestion with and Without Probiotic Supplementation","Inclusion Criteria:\n\n* Participants will be male or female between the ages of 18-35 years;\n* Participants have not been consuming any nutritional supplements for the preceding 6-week period;\n* Participants have not been consuming any ergogenic aids for the preceding 6-week period;\n* Participant has provided written and dated informed consent to participate in the study;\n* Participant is willing and able to comply with the protocol;\n* Participant is apparently healthy and free from disease, as determined by a health history questionnaire;\n\nExclusion Criteria:\n\n* Participant is allergic to any ingredient in the nutritional supplement or placebo;\n* Participant is not pregnant or trying to become pregnant, nor breast feeding;\n* Participant reports any unusual adverse events associated with this study that in consultation with the study investigators or their doctor recommends removal from the study;\n* Participant currently ingests nicotine or has quit within the last 6 months;","35 Years",{"count":92,"type":23},30,[26],"The purpose of this study is to examine the rate and concentration of amino acid absorption after a three-week pattern of milk protein supplementation with and without the addition of a single strain probiotic.",[96,37],"Amino Acid Absorption","2024-11-20",{"date":99,"type":43},"2024-11-22",{"date":101,"type":23},"2024-12-02",{"date":103,"type":23},"2026-01-15",{"name":49,"class":50},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":17,"sex":113,"minAge":19,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100553016","effect-of-a-multi-strain-probiotic-on-recurrent-vulvovaginal-candidiasis-100553016","NCT06480604","Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis","A Pilot Clinical Trial Assessing the Effect of a Multi-strain Probiotic on the Risk of Recurrence and Severity of Symptoms in Females With Recurrent Vulvovaginal Candidiasis","PROVELIA","Inclusion Criteria:\n\nIndividuals meeting ALL of the following criteria will be enrolled for the study:\n\n1. Premenopausal women aged 18-50 years.\n2. Women with a culture-confirmed active episode caused by Candida spp. (albicans or non-albicans) reported within 24-48 hours of evidence of clinical symptoms. (No medications should have been initiated before the sample for culture is collected).\n3. Documented history of recurrence of at least 3 VVC episodes in the last 12 months confirmed by vaginal culture \u002Fclinical diagnosis.\n4. Culture growth of Candida spp. causing VVC.\n5. Random Capillary Blood Glucose of \\\u003C 110mg\u002Fdl.\n6. Willingness to consume the study products for the entire study duration.\n7. Willing to complete all study procedures and comply with study requirements.\n8. Willing to abstain from other supplements or medication.\n9. Ready to give voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria:\n\nIndividuals meeting ANY of the following criteria will be excluded from the study:\n\n1. Post-menopausal and peri-menopausal women.\n2. Pregnant\u002Fbreast-feeding women.\n3. Use of oral or vaginal anti-fungal medication in the last 14 days.\n4. Vaginal culture suggestive of bacterial vaginosis (Nugent's score of 7-10), trichomonas vaginalis or Gardnerella vaginalis.\n5. Participants found positive for Clotrimazole resistance, by vaginal culture \\& sensitivity at screening.\n6. Known allergy to Clotrimazole.\n7. Women not willing to use any form of vaginal medication during the study.\n8. Use of vaginal douching.\n9. Unwillingness to use an appropriate method of contraception.\n10. Diagnosed with compromised immune system, type I and\u002For type II diabetes mellitus, or malignancies.\n11. Use of corticosteroids therapy in the last 30 days.\n12. Use of oral\u002Fsystemic antimicrobial therapy in the last 30 days.\n13. Known allergy to the study products or azoles.\n14. Individuals with a history of frequent infections requiring antibiotic treatments.\n15. Participation in another clinical study(ies) in the last 3 months.\n16. Women who, in the opinion of the Investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the study.\n17. Women with uncontrolled hypertension with systolic blood pressure ≥ 140 mm Hg and\u002For diastolic blood pressure ≥ 90 mm Hg.\n18. Heavy alcohol drinkers defined as follows: For men, consuming more than 4 drinks on any day or more than 14 drinks\u002Fweek. For women, consuming more than 3 drinks on any day or more than 7 drinks\u002Fweek.\n19. Smokers.\n20. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the Investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the individual at undue risk.\n21. Presence of unstable, acutely symptomatic, or life-limiting illness.\n22. Use of any supplements (includes probiotics, post-biotics, herbal supplements, synbiotics, enzyme supplements, vitamins with probiotics) in the last 30 days.","FEMALE","50 Years",{"count":22,"type":23},[26],"This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).",[119],"Vulvovaginal Candidiasis",[29,37,121,122,123,124,125,126,127],"Recurrent","Vulvovaginal","Candidiasis","RVVC","Vaginal","Chronic","Infection","2024-11-05",{"date":130,"type":43},"2024-11-07",{"date":132,"type":43},"2024-10-15",{"date":134,"type":23},"2025-07",{"name":49,"class":50},6,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":4},"100551906","determination-of-the-safety-and-efficacy-of-two-probiotic-strains-100551906","NCT06466174","Determination of the Safety and Efficacy of Two Probiotic Strains","Determination of the Safety and Efficacy of Two Probiotic Strains in Adults With Mild to Moderate Gastrointestinal Discomfort","CODECS","Inclusion Criteria:\n\n1. Signed Informed consent form\n2. Healthy adults aged 18-65 years\n3. Subclinical mild to moderate gastrointestinal complaints (GSRS-IBS score 20-45 at baseline)\n\nExclusion Criteria:\n\n1. Presence of a serious congenital anomaly or chronic medical condition that would contraindicate participation, including history of major gastrointestinal surgery, chronic gastrointestinal illness, abnormal intestinal anatomy or significant abdominal disorder\n2. Severe chronic illnesses\n3. Known immunodeficiency\n4. Use of immunosuppressive agents (corticosteroids, methotrexate…)\n5. Presence of severe immunodeficient family members as provided by subjects self-report\n6. Pregnancy, 6 months postpartum period or current breastfeeding\n7. Women of childbearing age planning pregnancy during the course of the study\n8. Actively participating in another clinical study, having completed a clinical study in the past 60 days or being in the exclusion period of a previous clinical study\n9. Not able to understand and comply with requirements of the study\n10. Use of probiotics, prebiotics, postbiotics, antibiotics within 3 weeks of study commencement",{"count":146,"type":23},100,[26],"The goal of this study is to determine the safety and efficacy of two probiotic strains in adults with mild to moderate gastrointestinal discomfort. The main questions it aims to answer is whether 6-week administration of a probiotic can improve how the participant feels regarding their gut health. This is done by completing a weekly questionnaire and the results are compared between the 6 weeks the participants are on a placebo and the 6 weeks the participants are on the probiotic. Participants will also provide a blood sample, and stool sample at the start and end of each treatment. Similarly, the results from the blood samples and stool samples will be analysed to determine if there is any improvement in markers related to gut health.",[150],"Gastrointestinal Dysfunction",[69,152],"gastrointestinal discomfort","2024-06-17",{"date":155,"type":43},"2024-06-20",{"date":157,"type":23},"2024-06",{"date":80,"type":23},{"name":49,"class":50},""]